Leila Shafiei Kaleybar1,2, Ali Baradar Khoshfetrat3,4, Reza Rahbarghazi5,6, Hojjatollah Nozad Charoudeh5,7. 1. Chemical Engineering Faculty, Sahand University of Technology, 51335-1996, Tabriz, Iran. 2. Stem Cell and Tissue Engineering Research Laboratory, Sahand University of Technology, 51335-1996, Tabriz, Iran. 3. Chemical Engineering Faculty, Sahand University of Technology, 51335-1996, Tabriz, Iran. Khoshfetrat@sut.ac.ir. 4. Stem Cell and Tissue Engineering Research Laboratory, Sahand University of Technology, 51335-1996, Tabriz, Iran. Khoshfetrat@sut.ac.ir. 5. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 7. Anatomical Sciences Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
OBJECTIVE: The novel engineered bioprocess, which was designed and modeled to provide the clinically relevant cell numbers for different therapies in our previous work (Kaleybar et al. Food Bioprod Process 122:254-268, https://doi.org/10.1016/j.fbp.2020.04.012 , 2020), was evaluated by using U937 as hematopoietic model cells. RESULTS: The culture system showed a 30-fold expansion of U937 cells in one-step during a 10-day culture period. The cell growth profile, the substrate and oxygen consumptions, and byproduct formations were all in agreement with the model predications during 7 days. The cell proliferation decrease after 7 days was attributed to optional oxygen limiting condition in the last days of culture. The bioreactor culture system revealed also a slight enhancement of lactate dehydrogenase (LDH) production as compared to the 2D conventional culture system, indicating the low impact of shear stress on cellular damage in the dynamic system. CONCLUSIONS: The results demonstrated that the conceptual bioprocess for suspended stem cell production has a great potential in practice although additional experiments are required to improve the system.
OBJECTIVE: The novel engineered bioprocess, which was designed and modeled to provide the clinically relevant cell numbers for different therapies in our previous work (Kaleybar et al. Food Bioprod Process 122:254-268, https://doi.org/10.1016/j.fbp.2020.04.012 , 2020), was evaluated by using U937 as hematopoietic model cells. RESULTS: The culture system showed a 30-fold expansion of U937 cells in one-step during a 10-day culture period. The cell growth profile, the substrate and oxygen consumptions, and byproduct formations were all in agreement with the model predications during 7 days. The cell proliferation decrease after 7 days was attributed to optional oxygen limiting condition in the last days of culture. The bioreactor culture system revealed also a slight enhancement of lactate dehydrogenase (LDH) production as compared to the 2D conventional culture system, indicating the low impact of shear stress on cellular damage in the dynamic system. CONCLUSIONS: The results demonstrated that the conceptual bioprocess for suspended stem cell production has a great potential in practice although additional experiments are required to improve the system.
Entities:
Keywords:
Conceptual bioprocess; Mass production; Sequencing batch aeration; Stirred tank bioreactor; Suspended stem cell
Authors: Jens Klaus; Doris Herrmann; Iris Breitkreutz; Ute Hegenbart; Uta Mazitschek; Gerlinde Egerer; Friedrich W Cremer; Ray M Lowenthal; Johannes Huesing; Stefan Fruehauf; Thomas Moehler; Anthony D Ho; Hartmut Goldschmidt Journal: Eur J Haematol Date: 2006-09-28 Impact factor: 2.997